nodes	percent_of_prediction	percent_of_DWPC	metapath
Etodolac—UGT2B7—urinary bladder cancer	0.486	0.859	CbGaD
Etodolac—PTGS2—urinary bladder cancer	0.0801	0.142	CbGaD
Etodolac—UGT2B7—Epirubicin—urinary bladder cancer	0.0675	0.319	CbGbCtD
Etodolac—PTGS2—Cisplatin—urinary bladder cancer	0.0278	0.131	CbGbCtD
Etodolac—PTGS2—Etoposide—urinary bladder cancer	0.0273	0.129	CbGbCtD
Etodolac—PTGS1—Etoposide—urinary bladder cancer	0.0231	0.109	CbGbCtD
Etodolac—ALB—Fluorouracil—urinary bladder cancer	0.0206	0.0975	CbGbCtD
Etodolac—SLC22A6—Methotrexate—urinary bladder cancer	0.0134	0.0631	CbGbCtD
Etodolac—ALB—Methotrexate—urinary bladder cancer	0.0114	0.0538	CbGbCtD
Etodolac—CYP2C9—Fluorouracil—urinary bladder cancer	0.0111	0.0526	CbGbCtD
Etodolac—CYP2C9—Cisplatin—urinary bladder cancer	0.00945	0.0447	CbGbCtD
Etodolac—UGT1A10—renal system—urinary bladder cancer	0.00257	0.146	CbGeAlD
Etodolac—RXRA—renal system—urinary bladder cancer	0.00153	0.087	CbGeAlD
Etodolac—UGT2B7—prostate gland—urinary bladder cancer	0.00152	0.0866	CbGeAlD
Etodolac—CYP2C9—urine—urinary bladder cancer	0.00152	0.0862	CbGeAlD
Etodolac—UGT1A9—renal system—urinary bladder cancer	0.00129	0.0732	CbGeAlD
Etodolac—RXRA—female reproductive system—urinary bladder cancer	0.00123	0.0697	CbGeAlD
Etodolac—UGT2B7—renal system—urinary bladder cancer	0.00104	0.059	CbGeAlD
Etodolac—UGT2B7—female reproductive system—urinary bladder cancer	0.000832	0.0473	CbGeAlD
Etodolac—PTGS1—prostate gland—urinary bladder cancer	0.000497	0.0283	CbGeAlD
Etodolac—PTGS2—prostate gland—urinary bladder cancer	0.000475	0.027	CbGeAlD
Etodolac—PTGS1—seminal vesicle—urinary bladder cancer	0.000421	0.0239	CbGeAlD
Etodolac—PTGS2—seminal vesicle—urinary bladder cancer	0.000402	0.0228	CbGeAlD
Etodolac—PTGS1—epithelium—urinary bladder cancer	0.000366	0.0208	CbGeAlD
Etodolac—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000352	0.02	CbGeAlD
Etodolac—PTGS2—epithelium—urinary bladder cancer	0.000349	0.0198	CbGeAlD
Etodolac—PTGS1—renal system—urinary bladder cancer	0.000339	0.0193	CbGeAlD
Etodolac—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000337	0.0191	CbGeAlD
Etodolac—PTGS2—renal system—urinary bladder cancer	0.000324	0.0184	CbGeAlD
Etodolac—PTGS2—urethra—urinary bladder cancer	0.000318	0.0181	CbGeAlD
Etodolac—CYP2C9—female reproductive system—urinary bladder cancer	0.000297	0.0169	CbGeAlD
Etodolac—ALB—lymph node—urinary bladder cancer	0.000279	0.0158	CbGeAlD
Etodolac—PTGS1—female reproductive system—urinary bladder cancer	0.000272	0.0154	CbGeAlD
Etodolac—PTGS2—female reproductive system—urinary bladder cancer	0.00026	0.0147	CbGeAlD
Etodolac—PTGS1—vagina—urinary bladder cancer	0.000246	0.0139	CbGeAlD
Etodolac—PTGS2—vagina—urinary bladder cancer	0.000235	0.0133	CbGeAlD
Etodolac—PTGS1—lymph node—urinary bladder cancer	0.000159	0.00902	CbGeAlD
Etodolac—PTGS2—lymph node—urinary bladder cancer	0.000152	0.00862	CbGeAlD
Etodolac—Fatigue—Etoposide—urinary bladder cancer	8.25e-05	0.000707	CcSEcCtD
Etodolac—Stomatitis—Epirubicin—urinary bladder cancer	8.2e-05	0.000703	CcSEcCtD
Etodolac—Jaundice—Epirubicin—urinary bladder cancer	8.2e-05	0.000703	CcSEcCtD
Etodolac—Pain—Etoposide—urinary bladder cancer	8.19e-05	0.000702	CcSEcCtD
Etodolac—Constipation—Etoposide—urinary bladder cancer	8.19e-05	0.000702	CcSEcCtD
Etodolac—Conjunctivitis—Epirubicin—urinary bladder cancer	8.18e-05	0.000701	CcSEcCtD
Etodolac—Dysuria—Doxorubicin—urinary bladder cancer	8.16e-05	0.0007	CcSEcCtD
Etodolac—Neutropenia—Doxorubicin—urinary bladder cancer	8.16e-05	0.0007	CcSEcCtD
Etodolac—Hypersensitivity—Fluorouracil—urinary bladder cancer	8.12e-05	0.000696	CcSEcCtD
Etodolac—Haemoglobin—Methotrexate—urinary bladder cancer	8.11e-05	0.000695	CcSEcCtD
Etodolac—Haemorrhage—Methotrexate—urinary bladder cancer	8.07e-05	0.000692	CcSEcCtD
Etodolac—Hepatitis—Methotrexate—urinary bladder cancer	8.07e-05	0.000692	CcSEcCtD
Etodolac—Sweating—Epirubicin—urinary bladder cancer	8.07e-05	0.000691	CcSEcCtD
Etodolac—Pollakiuria—Doxorubicin—urinary bladder cancer	8.06e-05	0.000691	CcSEcCtD
Etodolac—Asthenia—Gemcitabine—urinary bladder cancer	8.04e-05	0.000689	CcSEcCtD
Etodolac—Haematuria—Epirubicin—urinary bladder cancer	8.02e-05	0.000688	CcSEcCtD
Etodolac—Pharyngitis—Methotrexate—urinary bladder cancer	8.01e-05	0.000687	CcSEcCtD
Etodolac—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	7.97e-05	0.000683	CcSEcCtD
Etodolac—Pruritus—Gemcitabine—urinary bladder cancer	7.93e-05	0.00068	CcSEcCtD
Etodolac—Nausea—Thiotepa—urinary bladder cancer	7.92e-05	0.000678	CcSEcCtD
Etodolac—Sinusitis—Epirubicin—urinary bladder cancer	7.89e-05	0.000677	CcSEcCtD
Etodolac—Feeling abnormal—Etoposide—urinary bladder cancer	7.89e-05	0.000676	CcSEcCtD
Etodolac—Hyperglycaemia—Doxorubicin—urinary bladder cancer	7.88e-05	0.000675	CcSEcCtD
Etodolac—Agranulocytosis—Epirubicin—urinary bladder cancer	7.85e-05	0.000673	CcSEcCtD
Etodolac—Pneumonia—Doxorubicin—urinary bladder cancer	7.83e-05	0.000671	CcSEcCtD
Etodolac—Gastrointestinal pain—Etoposide—urinary bladder cancer	7.83e-05	0.000671	CcSEcCtD
Etodolac—Pruritus—Fluorouracil—urinary bladder cancer	7.8e-05	0.000668	CcSEcCtD
Etodolac—Visual impairment—Methotrexate—urinary bladder cancer	7.78e-05	0.000667	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	7.72e-05	0.000662	CcSEcCtD
Etodolac—Hypersensitivity—Cisplatin—urinary bladder cancer	7.7e-05	0.00066	CcSEcCtD
Etodolac—Diarrhoea—Gemcitabine—urinary bladder cancer	7.67e-05	0.000657	CcSEcCtD
Etodolac—Renal failure—Doxorubicin—urinary bladder cancer	7.65e-05	0.000656	CcSEcCtD
Etodolac—Erythema multiforme—Methotrexate—urinary bladder cancer	7.63e-05	0.000654	CcSEcCtD
Etodolac—Urticaria—Etoposide—urinary bladder cancer	7.6e-05	0.000652	CcSEcCtD
Etodolac—Haemoglobin—Epirubicin—urinary bladder cancer	7.59e-05	0.000651	CcSEcCtD
Etodolac—Stomatitis—Doxorubicin—urinary bladder cancer	7.59e-05	0.00065	CcSEcCtD
Etodolac—Jaundice—Doxorubicin—urinary bladder cancer	7.59e-05	0.00065	CcSEcCtD
Etodolac—Rhinitis—Epirubicin—urinary bladder cancer	7.57e-05	0.000649	CcSEcCtD
Etodolac—Abdominal pain—Etoposide—urinary bladder cancer	7.57e-05	0.000649	CcSEcCtD
Etodolac—Body temperature increased—Etoposide—urinary bladder cancer	7.57e-05	0.000649	CcSEcCtD
Etodolac—Conjunctivitis—Doxorubicin—urinary bladder cancer	7.57e-05	0.000649	CcSEcCtD
Etodolac—Haemorrhage—Epirubicin—urinary bladder cancer	7.55e-05	0.000647	CcSEcCtD
Etodolac—Hepatitis—Epirubicin—urinary bladder cancer	7.55e-05	0.000647	CcSEcCtD
Etodolac—Diarrhoea—Fluorouracil—urinary bladder cancer	7.54e-05	0.000646	CcSEcCtD
Etodolac—Tinnitus—Methotrexate—urinary bladder cancer	7.52e-05	0.000645	CcSEcCtD
Etodolac—Asthenia—Cisplatin—urinary bladder cancer	7.5e-05	0.000643	CcSEcCtD
Etodolac—Pharyngitis—Epirubicin—urinary bladder cancer	7.5e-05	0.000643	CcSEcCtD
Etodolac—Sweating—Doxorubicin—urinary bladder cancer	7.46e-05	0.00064	CcSEcCtD
Etodolac—Haematuria—Doxorubicin—urinary bladder cancer	7.42e-05	0.000636	CcSEcCtD
Etodolac—Sinusitis—Doxorubicin—urinary bladder cancer	7.3e-05	0.000626	CcSEcCtD
Etodolac—Dizziness—Fluorouracil—urinary bladder cancer	7.29e-05	0.000625	CcSEcCtD
Etodolac—Visual impairment—Epirubicin—urinary bladder cancer	7.28e-05	0.000624	CcSEcCtD
Etodolac—Agranulocytosis—Doxorubicin—urinary bladder cancer	7.26e-05	0.000623	CcSEcCtD
Etodolac—Chills—Methotrexate—urinary bladder cancer	7.24e-05	0.000621	CcSEcCtD
Etodolac—Diarrhoea—Cisplatin—urinary bladder cancer	7.15e-05	0.000613	CcSEcCtD
Etodolac—Erythema multiforme—Epirubicin—urinary bladder cancer	7.14e-05	0.000612	CcSEcCtD
Etodolac—Alopecia—Methotrexate—urinary bladder cancer	7.13e-05	0.000611	CcSEcCtD
Etodolac—Vomiting—Gemcitabine—urinary bladder cancer	7.13e-05	0.000611	CcSEcCtD
Etodolac—Rash—Gemcitabine—urinary bladder cancer	7.07e-05	0.000606	CcSEcCtD
Etodolac—Dermatitis—Gemcitabine—urinary bladder cancer	7.06e-05	0.000605	CcSEcCtD
Etodolac—Hypersensitivity—Etoposide—urinary bladder cancer	7.05e-05	0.000605	CcSEcCtD
Etodolac—Tinnitus—Epirubicin—urinary bladder cancer	7.04e-05	0.000604	CcSEcCtD
Etodolac—Haemoglobin—Doxorubicin—urinary bladder cancer	7.02e-05	0.000602	CcSEcCtD
Etodolac—Headache—Gemcitabine—urinary bladder cancer	7.02e-05	0.000602	CcSEcCtD
Etodolac—Flushing—Epirubicin—urinary bladder cancer	7.01e-05	0.000601	CcSEcCtD
Etodolac—Vomiting—Fluorouracil—urinary bladder cancer	7.01e-05	0.000601	CcSEcCtD
Etodolac—Rhinitis—Doxorubicin—urinary bladder cancer	7.01e-05	0.000601	CcSEcCtD
Etodolac—Haemorrhage—Doxorubicin—urinary bladder cancer	6.99e-05	0.000599	CcSEcCtD
Etodolac—Hepatitis—Doxorubicin—urinary bladder cancer	6.99e-05	0.000599	CcSEcCtD
Etodolac—Rash—Fluorouracil—urinary bladder cancer	6.95e-05	0.000596	CcSEcCtD
Etodolac—Dermatitis—Fluorouracil—urinary bladder cancer	6.94e-05	0.000595	CcSEcCtD
Etodolac—Pharyngitis—Doxorubicin—urinary bladder cancer	6.94e-05	0.000595	CcSEcCtD
Etodolac—Headache—Fluorouracil—urinary bladder cancer	6.9e-05	0.000592	CcSEcCtD
Etodolac—Dysgeusia—Methotrexate—urinary bladder cancer	6.88e-05	0.00059	CcSEcCtD
Etodolac—Asthenia—Etoposide—urinary bladder cancer	6.87e-05	0.000589	CcSEcCtD
Etodolac—Chills—Epirubicin—urinary bladder cancer	6.78e-05	0.000581	CcSEcCtD
Etodolac—Pruritus—Etoposide—urinary bladder cancer	6.77e-05	0.000581	CcSEcCtD
Etodolac—Arrhythmia—Epirubicin—urinary bladder cancer	6.75e-05	0.000578	CcSEcCtD
Etodolac—Visual impairment—Doxorubicin—urinary bladder cancer	6.73e-05	0.000577	CcSEcCtD
Etodolac—Alopecia—Epirubicin—urinary bladder cancer	6.67e-05	0.000572	CcSEcCtD
Etodolac—Nausea—Gemcitabine—urinary bladder cancer	6.66e-05	0.000571	CcSEcCtD
Etodolac—Vomiting—Cisplatin—urinary bladder cancer	6.64e-05	0.000569	CcSEcCtD
Etodolac—Vision blurred—Methotrexate—urinary bladder cancer	6.62e-05	0.000568	CcSEcCtD
Etodolac—Erythema multiforme—Doxorubicin—urinary bladder cancer	6.61e-05	0.000566	CcSEcCtD
Etodolac—Rash—Cisplatin—urinary bladder cancer	6.59e-05	0.000565	CcSEcCtD
Etodolac—Dermatitis—Cisplatin—urinary bladder cancer	6.58e-05	0.000564	CcSEcCtD
Etodolac—Diarrhoea—Etoposide—urinary bladder cancer	6.55e-05	0.000561	CcSEcCtD
Etodolac—Nausea—Fluorouracil—urinary bladder cancer	6.55e-05	0.000561	CcSEcCtD
Etodolac—Ill-defined disorder—Methotrexate—urinary bladder cancer	6.52e-05	0.000559	CcSEcCtD
Etodolac—Tinnitus—Doxorubicin—urinary bladder cancer	6.52e-05	0.000558	CcSEcCtD
Etodolac—Anaemia—Methotrexate—urinary bladder cancer	6.49e-05	0.000557	CcSEcCtD
Etodolac—Flushing—Doxorubicin—urinary bladder cancer	6.49e-05	0.000556	CcSEcCtD
Etodolac—Flatulence—Epirubicin—urinary bladder cancer	6.48e-05	0.000555	CcSEcCtD
Etodolac—Tension—Epirubicin—urinary bladder cancer	6.45e-05	0.000553	CcSEcCtD
Etodolac—Dysgeusia—Epirubicin—urinary bladder cancer	6.44e-05	0.000552	CcSEcCtD
Etodolac—Nervousness—Epirubicin—urinary bladder cancer	6.39e-05	0.000547	CcSEcCtD
Etodolac—Malaise—Methotrexate—urinary bladder cancer	6.34e-05	0.000543	CcSEcCtD
Etodolac—Dizziness—Etoposide—urinary bladder cancer	6.33e-05	0.000543	CcSEcCtD
Etodolac—Vertigo—Methotrexate—urinary bladder cancer	6.31e-05	0.000541	CcSEcCtD
Etodolac—Leukopenia—Methotrexate—urinary bladder cancer	6.29e-05	0.000539	CcSEcCtD
Etodolac—Chills—Doxorubicin—urinary bladder cancer	6.27e-05	0.000537	CcSEcCtD
Etodolac—Arrhythmia—Doxorubicin—urinary bladder cancer	6.24e-05	0.000535	CcSEcCtD
Etodolac—Nausea—Cisplatin—urinary bladder cancer	6.21e-05	0.000532	CcSEcCtD
Etodolac—Vision blurred—Epirubicin—urinary bladder cancer	6.2e-05	0.000531	CcSEcCtD
Etodolac—Alopecia—Doxorubicin—urinary bladder cancer	6.17e-05	0.000529	CcSEcCtD
Etodolac—Ill-defined disorder—Epirubicin—urinary bladder cancer	6.1e-05	0.000523	CcSEcCtD
Etodolac—Convulsion—Methotrexate—urinary bladder cancer	6.09e-05	0.000522	CcSEcCtD
Etodolac—Vomiting—Etoposide—urinary bladder cancer	6.09e-05	0.000522	CcSEcCtD
Etodolac—Anaemia—Epirubicin—urinary bladder cancer	6.08e-05	0.000521	CcSEcCtD
Etodolac—Rash—Etoposide—urinary bladder cancer	6.04e-05	0.000517	CcSEcCtD
Etodolac—Dermatitis—Etoposide—urinary bladder cancer	6.03e-05	0.000517	CcSEcCtD
Etodolac—Headache—Etoposide—urinary bladder cancer	6e-05	0.000514	CcSEcCtD
Etodolac—Flatulence—Doxorubicin—urinary bladder cancer	5.99e-05	0.000514	CcSEcCtD
Etodolac—Myalgia—Methotrexate—urinary bladder cancer	5.98e-05	0.000513	CcSEcCtD
Etodolac—Arthralgia—Methotrexate—urinary bladder cancer	5.98e-05	0.000513	CcSEcCtD
Etodolac—Tension—Doxorubicin—urinary bladder cancer	5.97e-05	0.000512	CcSEcCtD
Etodolac—Dysgeusia—Doxorubicin—urinary bladder cancer	5.96e-05	0.000511	CcSEcCtD
Etodolac—Malaise—Epirubicin—urinary bladder cancer	5.93e-05	0.000508	CcSEcCtD
Etodolac—Discomfort—Methotrexate—urinary bladder cancer	5.91e-05	0.000507	CcSEcCtD
Etodolac—Nervousness—Doxorubicin—urinary bladder cancer	5.91e-05	0.000506	CcSEcCtD
Etodolac—Vertigo—Epirubicin—urinary bladder cancer	5.91e-05	0.000506	CcSEcCtD
Etodolac—Syncope—Epirubicin—urinary bladder cancer	5.9e-05	0.000505	CcSEcCtD
Etodolac—Leukopenia—Epirubicin—urinary bladder cancer	5.88e-05	0.000504	CcSEcCtD
Etodolac—Palpitations—Epirubicin—urinary bladder cancer	5.81e-05	0.000498	CcSEcCtD
Etodolac—Confusional state—Methotrexate—urinary bladder cancer	5.78e-05	0.000496	CcSEcCtD
Etodolac—Loss of consciousness—Epirubicin—urinary bladder cancer	5.78e-05	0.000495	CcSEcCtD
Etodolac—Anaphylactic shock—Methotrexate—urinary bladder cancer	5.73e-05	0.000491	CcSEcCtD
Etodolac—Vision blurred—Doxorubicin—urinary bladder cancer	5.73e-05	0.000491	CcSEcCtD
Etodolac—Convulsion—Epirubicin—urinary bladder cancer	5.7e-05	0.000488	CcSEcCtD
Etodolac—Infection—Methotrexate—urinary bladder cancer	5.7e-05	0.000488	CcSEcCtD
Etodolac—Nausea—Etoposide—urinary bladder cancer	5.69e-05	0.000487	CcSEcCtD
Etodolac—Hypertension—Epirubicin—urinary bladder cancer	5.68e-05	0.000487	CcSEcCtD
Etodolac—Ill-defined disorder—Doxorubicin—urinary bladder cancer	5.64e-05	0.000484	CcSEcCtD
Etodolac—Anaemia—Doxorubicin—urinary bladder cancer	5.62e-05	0.000482	CcSEcCtD
Etodolac—Thrombocytopenia—Methotrexate—urinary bladder cancer	5.61e-05	0.000481	CcSEcCtD
Etodolac—Arthralgia—Epirubicin—urinary bladder cancer	5.6e-05	0.00048	CcSEcCtD
Etodolac—Myalgia—Epirubicin—urinary bladder cancer	5.6e-05	0.00048	CcSEcCtD
Etodolac—Anxiety—Epirubicin—urinary bladder cancer	5.58e-05	0.000478	CcSEcCtD
Etodolac—Hyperhidrosis—Methotrexate—urinary bladder cancer	5.54e-05	0.000475	CcSEcCtD
Etodolac—Discomfort—Epirubicin—urinary bladder cancer	5.53e-05	0.000474	CcSEcCtD
Etodolac—Malaise—Doxorubicin—urinary bladder cancer	5.49e-05	0.00047	CcSEcCtD
Etodolac—Dry mouth—Epirubicin—urinary bladder cancer	5.47e-05	0.000469	CcSEcCtD
Etodolac—Vertigo—Doxorubicin—urinary bladder cancer	5.47e-05	0.000468	CcSEcCtD
Etodolac—Anorexia—Methotrexate—urinary bladder cancer	5.47e-05	0.000468	CcSEcCtD
Etodolac—Syncope—Doxorubicin—urinary bladder cancer	5.46e-05	0.000468	CcSEcCtD
Etodolac—Leukopenia—Doxorubicin—urinary bladder cancer	5.45e-05	0.000467	CcSEcCtD
Etodolac—Confusional state—Epirubicin—urinary bladder cancer	5.41e-05	0.000464	CcSEcCtD
Etodolac—Palpitations—Doxorubicin—urinary bladder cancer	5.38e-05	0.000461	CcSEcCtD
Etodolac—Oedema—Epirubicin—urinary bladder cancer	5.37e-05	0.00046	CcSEcCtD
Etodolac—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.37e-05	0.00046	CcSEcCtD
Etodolac—Hypotension—Methotrexate—urinary bladder cancer	5.36e-05	0.000459	CcSEcCtD
Etodolac—Loss of consciousness—Doxorubicin—urinary bladder cancer	5.35e-05	0.000458	CcSEcCtD
Etodolac—Infection—Epirubicin—urinary bladder cancer	5.33e-05	0.000457	CcSEcCtD
Etodolac—Shock—Epirubicin—urinary bladder cancer	5.28e-05	0.000453	CcSEcCtD
Etodolac—Convulsion—Doxorubicin—urinary bladder cancer	5.27e-05	0.000452	CcSEcCtD
Etodolac—Thrombocytopenia—Epirubicin—urinary bladder cancer	5.25e-05	0.00045	CcSEcCtD
Etodolac—Hypertension—Doxorubicin—urinary bladder cancer	5.25e-05	0.00045	CcSEcCtD
Etodolac—Tachycardia—Epirubicin—urinary bladder cancer	5.24e-05	0.000449	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.22e-05	0.000448	CcSEcCtD
Etodolac—Hyperhidrosis—Epirubicin—urinary bladder cancer	5.19e-05	0.000445	CcSEcCtD
Etodolac—Insomnia—Methotrexate—urinary bladder cancer	5.19e-05	0.000445	CcSEcCtD
Etodolac—Arthralgia—Doxorubicin—urinary bladder cancer	5.18e-05	0.000444	CcSEcCtD
Etodolac—Myalgia—Doxorubicin—urinary bladder cancer	5.18e-05	0.000444	CcSEcCtD
Etodolac—Anxiety—Doxorubicin—urinary bladder cancer	5.16e-05	0.000442	CcSEcCtD
Etodolac—Paraesthesia—Methotrexate—urinary bladder cancer	5.15e-05	0.000441	CcSEcCtD
Etodolac—Discomfort—Doxorubicin—urinary bladder cancer	5.12e-05	0.000439	CcSEcCtD
Etodolac—Anorexia—Epirubicin—urinary bladder cancer	5.11e-05	0.000438	CcSEcCtD
Etodolac—Dyspnoea—Methotrexate—urinary bladder cancer	5.11e-05	0.000438	CcSEcCtD
Etodolac—Somnolence—Methotrexate—urinary bladder cancer	5.1e-05	0.000437	CcSEcCtD
Etodolac—Dry mouth—Doxorubicin—urinary bladder cancer	5.06e-05	0.000434	CcSEcCtD
Etodolac—Dyspepsia—Methotrexate—urinary bladder cancer	5.05e-05	0.000433	CcSEcCtD
Etodolac—Hypotension—Epirubicin—urinary bladder cancer	5.01e-05	0.00043	CcSEcCtD
Etodolac—Confusional state—Doxorubicin—urinary bladder cancer	5.01e-05	0.000429	CcSEcCtD
Etodolac—Decreased appetite—Methotrexate—urinary bladder cancer	4.98e-05	0.000427	CcSEcCtD
Etodolac—Oedema—Doxorubicin—urinary bladder cancer	4.96e-05	0.000426	CcSEcCtD
Etodolac—Anaphylactic shock—Doxorubicin—urinary bladder cancer	4.96e-05	0.000426	CcSEcCtD
Etodolac—Fatigue—Methotrexate—urinary bladder cancer	4.94e-05	0.000424	CcSEcCtD
Etodolac—Infection—Doxorubicin—urinary bladder cancer	4.93e-05	0.000423	CcSEcCtD
Etodolac—Pain—Methotrexate—urinary bladder cancer	4.9e-05	0.00042	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	4.89e-05	0.000419	CcSEcCtD
Etodolac—Shock—Doxorubicin—urinary bladder cancer	4.88e-05	0.000419	CcSEcCtD
Etodolac—Thrombocytopenia—Doxorubicin—urinary bladder cancer	4.86e-05	0.000417	CcSEcCtD
Etodolac—Insomnia—Epirubicin—urinary bladder cancer	4.85e-05	0.000416	CcSEcCtD
Etodolac—Tachycardia—Doxorubicin—urinary bladder cancer	4.85e-05	0.000415	CcSEcCtD
Etodolac—Paraesthesia—Epirubicin—urinary bladder cancer	4.82e-05	0.000413	CcSEcCtD
Etodolac—Hyperhidrosis—Doxorubicin—urinary bladder cancer	4.8e-05	0.000411	CcSEcCtD
Etodolac—Dyspnoea—Epirubicin—urinary bladder cancer	4.78e-05	0.00041	CcSEcCtD
Etodolac—Somnolence—Epirubicin—urinary bladder cancer	4.77e-05	0.000409	CcSEcCtD
Etodolac—Anorexia—Doxorubicin—urinary bladder cancer	4.73e-05	0.000406	CcSEcCtD
Etodolac—Feeling abnormal—Methotrexate—urinary bladder cancer	4.72e-05	0.000405	CcSEcCtD
Etodolac—Dyspepsia—Epirubicin—urinary bladder cancer	4.72e-05	0.000405	CcSEcCtD
Etodolac—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.69e-05	0.000402	CcSEcCtD
Etodolac—Decreased appetite—Epirubicin—urinary bladder cancer	4.66e-05	0.0004	CcSEcCtD
Etodolac—Hypotension—Doxorubicin—urinary bladder cancer	4.64e-05	0.000398	CcSEcCtD
Etodolac—Fatigue—Epirubicin—urinary bladder cancer	4.63e-05	0.000397	CcSEcCtD
Etodolac—Constipation—Epirubicin—urinary bladder cancer	4.59e-05	0.000393	CcSEcCtD
Etodolac—Pain—Epirubicin—urinary bladder cancer	4.59e-05	0.000393	CcSEcCtD
Etodolac—Urticaria—Methotrexate—urinary bladder cancer	4.55e-05	0.00039	CcSEcCtD
Etodolac—Abdominal pain—Methotrexate—urinary bladder cancer	4.53e-05	0.000389	CcSEcCtD
Etodolac—Body temperature increased—Methotrexate—urinary bladder cancer	4.53e-05	0.000389	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.52e-05	0.000388	CcSEcCtD
Etodolac—Insomnia—Doxorubicin—urinary bladder cancer	4.49e-05	0.000385	CcSEcCtD
Etodolac—Paraesthesia—Doxorubicin—urinary bladder cancer	4.46e-05	0.000382	CcSEcCtD
Etodolac—Dyspnoea—Doxorubicin—urinary bladder cancer	4.43e-05	0.000379	CcSEcCtD
Etodolac—Feeling abnormal—Epirubicin—urinary bladder cancer	4.42e-05	0.000379	CcSEcCtD
Etodolac—Somnolence—Doxorubicin—urinary bladder cancer	4.41e-05	0.000378	CcSEcCtD
Etodolac—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.39e-05	0.000376	CcSEcCtD
Etodolac—Dyspepsia—Doxorubicin—urinary bladder cancer	4.37e-05	0.000375	CcSEcCtD
Etodolac—Decreased appetite—Doxorubicin—urinary bladder cancer	4.32e-05	0.00037	CcSEcCtD
Etodolac—Fatigue—Doxorubicin—urinary bladder cancer	4.28e-05	0.000367	CcSEcCtD
Etodolac—Urticaria—Epirubicin—urinary bladder cancer	4.26e-05	0.000365	CcSEcCtD
Etodolac—Constipation—Doxorubicin—urinary bladder cancer	4.25e-05	0.000364	CcSEcCtD
Etodolac—Pain—Doxorubicin—urinary bladder cancer	4.25e-05	0.000364	CcSEcCtD
Etodolac—Abdominal pain—Epirubicin—urinary bladder cancer	4.24e-05	0.000364	CcSEcCtD
Etodolac—Body temperature increased—Epirubicin—urinary bladder cancer	4.24e-05	0.000364	CcSEcCtD
Etodolac—Hypersensitivity—Methotrexate—urinary bladder cancer	4.22e-05	0.000362	CcSEcCtD
Etodolac—Asthenia—Methotrexate—urinary bladder cancer	4.11e-05	0.000353	CcSEcCtD
Etodolac—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.09e-05	0.000351	CcSEcCtD
Etodolac—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.06e-05	0.000348	CcSEcCtD
Etodolac—Pruritus—Methotrexate—urinary bladder cancer	4.06e-05	0.000348	CcSEcCtD
Etodolac—Hypersensitivity—Epirubicin—urinary bladder cancer	3.95e-05	0.000339	CcSEcCtD
Etodolac—Urticaria—Doxorubicin—urinary bladder cancer	3.94e-05	0.000338	CcSEcCtD
Etodolac—Abdominal pain—Doxorubicin—urinary bladder cancer	3.92e-05	0.000336	CcSEcCtD
Etodolac—Body temperature increased—Doxorubicin—urinary bladder cancer	3.92e-05	0.000336	CcSEcCtD
Etodolac—Diarrhoea—Methotrexate—urinary bladder cancer	3.92e-05	0.000336	CcSEcCtD
Etodolac—Asthenia—Epirubicin—urinary bladder cancer	3.85e-05	0.00033	CcSEcCtD
Etodolac—Pruritus—Epirubicin—urinary bladder cancer	3.8e-05	0.000325	CcSEcCtD
Etodolac—Dizziness—Methotrexate—urinary bladder cancer	3.79e-05	0.000325	CcSEcCtD
Etodolac—Diarrhoea—Epirubicin—urinary bladder cancer	3.67e-05	0.000315	CcSEcCtD
Etodolac—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.66e-05	0.000314	CcSEcCtD
Etodolac—Vomiting—Methotrexate—urinary bladder cancer	3.65e-05	0.000312	CcSEcCtD
Etodolac—Rash—Methotrexate—urinary bladder cancer	3.61e-05	0.00031	CcSEcCtD
Etodolac—Dermatitis—Methotrexate—urinary bladder cancer	3.61e-05	0.00031	CcSEcCtD
Etodolac—Headache—Methotrexate—urinary bladder cancer	3.59e-05	0.000308	CcSEcCtD
Etodolac—Asthenia—Doxorubicin—urinary bladder cancer	3.56e-05	0.000305	CcSEcCtD
Etodolac—Dizziness—Epirubicin—urinary bladder cancer	3.55e-05	0.000304	CcSEcCtD
Etodolac—Pruritus—Doxorubicin—urinary bladder cancer	3.51e-05	0.000301	CcSEcCtD
Etodolac—Vomiting—Epirubicin—urinary bladder cancer	3.41e-05	0.000292	CcSEcCtD
Etodolac—Nausea—Methotrexate—urinary bladder cancer	3.41e-05	0.000292	CcSEcCtD
Etodolac—Diarrhoea—Doxorubicin—urinary bladder cancer	3.4e-05	0.000291	CcSEcCtD
Etodolac—Rash—Epirubicin—urinary bladder cancer	3.38e-05	0.00029	CcSEcCtD
Etodolac—Dermatitis—Epirubicin—urinary bladder cancer	3.38e-05	0.00029	CcSEcCtD
Etodolac—Headache—Epirubicin—urinary bladder cancer	3.36e-05	0.000288	CcSEcCtD
Etodolac—Dizziness—Doxorubicin—urinary bladder cancer	3.28e-05	0.000281	CcSEcCtD
Etodolac—Nausea—Epirubicin—urinary bladder cancer	3.19e-05	0.000273	CcSEcCtD
Etodolac—Vomiting—Doxorubicin—urinary bladder cancer	3.16e-05	0.000271	CcSEcCtD
Etodolac—Rash—Doxorubicin—urinary bladder cancer	3.13e-05	0.000268	CcSEcCtD
Etodolac—Dermatitis—Doxorubicin—urinary bladder cancer	3.13e-05	0.000268	CcSEcCtD
Etodolac—Headache—Doxorubicin—urinary bladder cancer	3.11e-05	0.000267	CcSEcCtD
Etodolac—Nausea—Doxorubicin—urinary bladder cancer	2.95e-05	0.000253	CcSEcCtD
Etodolac—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	2.06e-05	0.000235	CbGpPWpGaD
Etodolac—RXRA—Metabolism—HPGDS—urinary bladder cancer	2.06e-05	0.000234	CbGpPWpGaD
Etodolac—RXRA—Metabolism—ENO2—urinary bladder cancer	2.06e-05	0.000234	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.05e-05	0.000233	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.03e-05	0.000231	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—TYMP—urinary bladder cancer	2.02e-05	0.00023	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PRSS3—urinary bladder cancer	2.01e-05	0.000229	CbGpPWpGaD
Etodolac—RXRA—Metabolism—GSTT1—urinary bladder cancer	2e-05	0.000227	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—RHOA—urinary bladder cancer	1.99e-05	0.000227	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.97e-05	0.000224	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.96e-05	0.000224	CbGpPWpGaD
Etodolac—ALB—Metabolism—UGT2B7—urinary bladder cancer	1.96e-05	0.000223	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.94e-05	0.000221	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—RRM2—urinary bladder cancer	1.94e-05	0.00022	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	1.9e-05	0.000217	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.9e-05	0.000216	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.9e-05	0.000216	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	1.89e-05	0.000215	CbGpPWpGaD
Etodolac—RXRA—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.87e-05	0.000213	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	1.85e-05	0.000211	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—ERBB2—urinary bladder cancer	1.84e-05	0.00021	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—NAT2—urinary bladder cancer	1.83e-05	0.000208	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.82e-05	0.000207	CbGpPWpGaD
Etodolac—PTGS2—Disease—LIG1—urinary bladder cancer	1.82e-05	0.000207	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.81e-05	0.000206	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—ENO2—urinary bladder cancer	1.79e-05	0.000204	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—HPGDS—urinary bladder cancer	1.79e-05	0.000204	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.78e-05	0.000203	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—NQO1—urinary bladder cancer	1.78e-05	0.000203	CbGpPWpGaD
Etodolac—ALB—Metabolism—CYP4B1—urinary bladder cancer	1.77e-05	0.000201	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.76e-05	0.0002	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	1.75e-05	0.0002	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—NAT1—urinary bladder cancer	1.75e-05	0.0002	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—GSTP1—urinary bladder cancer	1.74e-05	0.000199	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GSTT1—urinary bladder cancer	1.74e-05	0.000198	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	1.73e-05	0.000197	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.73e-05	0.000197	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.71e-05	0.000195	CbGpPWpGaD
Etodolac—ALB—Hemostasis—IFNA2—urinary bladder cancer	1.68e-05	0.000192	CbGpPWpGaD
Etodolac—ALB—Metabolism—SLC19A1—urinary bladder cancer	1.67e-05	0.00019	CbGpPWpGaD
Etodolac—RXRA—Metabolism—NQO1—urinary bladder cancer	1.66e-05	0.000189	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.64e-05	0.000187	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—NCOR1—urinary bladder cancer	1.64e-05	0.000186	CbGpPWpGaD
Etodolac—ALB—Metabolism—PRSS3—urinary bladder cancer	1.62e-05	0.000185	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—TYMS—urinary bladder cancer	1.62e-05	0.000185	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.61e-05	0.000183	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.61e-05	0.000183	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—TYMP—urinary bladder cancer	1.61e-05	0.000183	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	1.6e-05	0.000183	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—GSTM1—urinary bladder cancer	1.6e-05	0.000183	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—NCOR1—urinary bladder cancer	1.6e-05	0.000183	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—MMP9—urinary bladder cancer	1.58e-05	0.00018	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—RRM2—urinary bladder cancer	1.58e-05	0.00018	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.58e-05	0.000179	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.54e-05	0.000176	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.54e-05	0.000175	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—ERCC2—urinary bladder cancer	1.54e-05	0.000175	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—GPX1—urinary bladder cancer	1.54e-05	0.000175	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—ERCC2—urinary bladder cancer	1.51e-05	0.000172	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—EP300—urinary bladder cancer	1.5e-05	0.000171	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—GSTP1—urinary bladder cancer	1.48e-05	0.000169	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.47e-05	0.000167	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—HPGDS—urinary bladder cancer	1.46e-05	0.000166	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ENO2—urinary bladder cancer	1.46e-05	0.000166	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—SRC—urinary bladder cancer	1.46e-05	0.000166	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.46e-05	0.000166	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.45e-05	0.000165	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—NAT2—urinary bladder cancer	1.45e-05	0.000165	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	1.45e-05	0.000165	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—NQO1—urinary bladder cancer	1.45e-05	0.000165	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	1.44e-05	0.000165	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GSTT1—urinary bladder cancer	1.42e-05	0.000161	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—MTHFR—urinary bladder cancer	1.42e-05	0.000161	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.4e-05	0.00016	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.4e-05	0.00016	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.4e-05	0.000159	CbGpPWpGaD
Etodolac—RXRA—Generic Transcription Pathway—MYC—urinary bladder cancer	1.39e-05	0.000158	CbGpPWpGaD
Etodolac—PTGS2—Disease—ENO2—urinary bladder cancer	1.39e-05	0.000158	CbGpPWpGaD
Etodolac—RXRA—Metabolism—GSTP1—urinary bladder cancer	1.38e-05	0.000158	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—TYMS—urinary bladder cancer	1.38e-05	0.000157	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.36e-05	0.000155	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—NCOR1—urinary bladder cancer	1.36e-05	0.000155	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—GSTM1—urinary bladder cancer	1.36e-05	0.000155	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.34e-05	0.000152	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.33e-05	0.000151	CbGpPWpGaD
Etodolac—PTGS2—Disease—RBX1—urinary bladder cancer	1.31e-05	0.00015	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—GPX1—urinary bladder cancer	1.31e-05	0.000149	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.3e-05	0.000148	CbGpPWpGaD
Etodolac—ALB—Metabolism—TYMP—urinary bladder cancer	1.3e-05	0.000148	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.29e-05	0.000147	CbGpPWpGaD
Etodolac—RXRA—Metabolism—TYMS—urinary bladder cancer	1.29e-05	0.000147	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—ESR1—urinary bladder cancer	1.28e-05	0.000146	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—ERCC2—urinary bladder cancer	1.28e-05	0.000146	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—EGFR—urinary bladder cancer	1.28e-05	0.000146	CbGpPWpGaD
Etodolac—RXRA—Metabolism—NCOR1—urinary bladder cancer	1.27e-05	0.000145	CbGpPWpGaD
Etodolac—RXRA—Metabolism—GSTM1—urinary bladder cancer	1.27e-05	0.000145	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	1.27e-05	0.000144	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—RRM2—urinary bladder cancer	1.25e-05	0.000143	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.25e-05	0.000142	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.22e-05	0.000139	CbGpPWpGaD
Etodolac—RXRA—Metabolism—GPX1—urinary bladder cancer	1.22e-05	0.000139	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—TNF—urinary bladder cancer	1.22e-05	0.000139	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—KRAS—urinary bladder cancer	1.21e-05	0.000137	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GSTP1—urinary bladder cancer	1.21e-05	0.000137	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—MTHFR—urinary bladder cancer	1.2e-05	0.000137	CbGpPWpGaD
Etodolac—RXRA—Metabolism—ERCC2—urinary bladder cancer	1.2e-05	0.000136	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PLAU—urinary bladder cancer	1.19e-05	0.000136	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—NQO1—urinary bladder cancer	1.18e-05	0.000134	CbGpPWpGaD
Etodolac—PTGS2—Disease—JAG1—urinary bladder cancer	1.18e-05	0.000134	CbGpPWpGaD
Etodolac—ALB—Metabolism—NAT2—urinary bladder cancer	1.17e-05	0.000134	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—PPARG—urinary bladder cancer	1.17e-05	0.000133	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.17e-05	0.000133	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—HPGDS—urinary bladder cancer	1.16e-05	0.000132	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ENO2—urinary bladder cancer	1.16e-05	0.000132	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.15e-05	0.000131	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PPARG—urinary bladder cancer	1.15e-05	0.000131	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.14e-05	0.00013	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—CREBBP—urinary bladder cancer	1.13e-05	0.000128	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GSTT1—urinary bladder cancer	1.13e-05	0.000128	CbGpPWpGaD
Etodolac—RXRA—Metabolism—MTHFR—urinary bladder cancer	1.12e-05	0.000128	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—TYMS—urinary bladder cancer	1.12e-05	0.000128	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.11e-05	0.000126	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GSTM1—urinary bladder cancer	1.11e-05	0.000126	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—NCOR1—urinary bladder cancer	1.11e-05	0.000126	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—CREBBP—urinary bladder cancer	1.1e-05	0.000126	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.07e-05	0.000121	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.06e-05	0.000121	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GPX1—urinary bladder cancer	1.06e-05	0.000121	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—ERCC2—urinary bladder cancer	1.04e-05	0.000119	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—HRAS—urinary bladder cancer	1.03e-05	0.000117	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.02e-05	0.000116	CbGpPWpGaD
Etodolac—ALB—Metabolism—RRM2—urinary bladder cancer	1.01e-05	0.000115	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.97e-06	0.000114	CbGpPWpGaD
Etodolac—ALB—Hemostasis—CREBBP—urinary bladder cancer	9.85e-06	0.000112	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GSTP1—urinary bladder cancer	9.83e-06	0.000112	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—MTHFR—urinary bladder cancer	9.79e-06	0.000111	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PPARG—urinary bladder cancer	9.77e-06	0.000111	CbGpPWpGaD
Etodolac—ALB—Hemostasis—IGF1—urinary bladder cancer	9.73e-06	0.000111	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—NAT2—urinary bladder cancer	9.61e-06	0.000109	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.51e-06	0.000108	CbGpPWpGaD
Etodolac—ALB—Metabolism—HPGDS—urinary bladder cancer	9.39e-06	0.000107	CbGpPWpGaD
Etodolac—ALB—Metabolism—ENO2—urinary bladder cancer	9.39e-06	0.000107	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—CREBBP—urinary bladder cancer	9.39e-06	0.000107	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—NQO1—urinary bladder cancer	9.35e-06	0.000107	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.33e-06	0.000106	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—TYMS—urinary bladder cancer	9.14e-06	0.000104	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PPARG—urinary bladder cancer	9.11e-06	0.000104	CbGpPWpGaD
Etodolac—ALB—Metabolism—GSTT1—urinary bladder cancer	9.11e-06	0.000104	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PTGS2—urinary bladder cancer	9.04e-06	0.000103	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GSTM1—urinary bladder cancer	9.03e-06	0.000103	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—NCOR1—urinary bladder cancer	9.03e-06	0.000103	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.97e-06	0.000102	CbGpPWpGaD
Etodolac—ALB—Hemostasis—RHOA—urinary bladder cancer	8.91e-06	0.000101	CbGpPWpGaD
Etodolac—RXRA—Metabolism—CREBBP—urinary bladder cancer	8.76e-06	9.97e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GPX1—urinary bladder cancer	8.65e-06	9.85e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—NCOR1—urinary bladder cancer	8.56e-06	9.75e-05	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.53e-06	9.71e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ERCC2—urinary bladder cancer	8.49e-06	9.67e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—RRM2—urinary bladder cancer	8.3e-06	9.45e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—ERCC2—urinary bladder cancer	8.05e-06	9.17e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—MTHFR—urinary bladder cancer	7.98e-06	9.09e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PPARG—urinary bladder cancer	7.94e-06	9.04e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.92e-06	9.01e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PTEN—urinary bladder cancer	7.88e-06	8.98e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GSTP1—urinary bladder cancer	7.8e-06	8.88e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PTGS2—urinary bladder cancer	7.69e-06	8.75e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	7.69e-06	8.75e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ENO2—urinary bladder cancer	7.69e-06	8.75e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	7.64e-06	8.7e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	7.63e-06	8.69e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—NQO1—urinary bladder cancer	7.57e-06	8.62e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—MTHFR—urinary bladder cancer	7.57e-06	8.62e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.55e-06	8.6e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—TERT—urinary bladder cancer	7.55e-06	8.59e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—EP300—urinary bladder cancer	7.52e-06	8.56e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—IL2—urinary bladder cancer	7.48e-06	8.51e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	7.45e-06	8.49e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.34e-06	8.36e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	7.34e-06	8.36e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—TYMS—urinary bladder cancer	7.25e-06	8.26e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—NCOR1—urinary bladder cancer	7.17e-06	8.16e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GSTM1—urinary bladder cancer	7.17e-06	8.16e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PTGS2—urinary bladder cancer	7.17e-06	8.16e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—FGFR3—urinary bladder cancer	6.92e-06	7.88e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GPX1—urinary bladder cancer	6.87e-06	7.82e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ERCC2—urinary bladder cancer	6.74e-06	7.68e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—EP300—urinary bladder cancer	6.71e-06	7.64e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PTEN—urinary bladder cancer	6.7e-06	7.63e-05	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—MYC—urinary bladder cancer	6.68e-06	7.61e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—SRC—urinary bladder cancer	6.52e-06	7.43e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PPARG—urinary bladder cancer	6.47e-06	7.37e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.4e-06	7.29e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—EP300—urinary bladder cancer	6.39e-06	7.28e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—MTHFR—urinary bladder cancer	6.34e-06	7.22e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GSTP1—urinary bladder cancer	6.31e-06	7.19e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PTEN—urinary bladder cancer	6.25e-06	7.12e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	6.25e-06	7.11e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CREBBP—urinary bladder cancer	6.22e-06	7.08e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—NQO1—urinary bladder cancer	6.19e-06	7.05e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.11e-06	6.95e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.01e-06	6.84e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—EP300—urinary bladder cancer	5.96e-06	6.79e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—CREBBP—urinary bladder cancer	5.89e-06	6.71e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—TYMS—urinary bladder cancer	5.87e-06	6.68e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GSTM1—urinary bladder cancer	5.8e-06	6.61e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—NCOR1—urinary bladder cancer	5.8e-06	6.61e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GPX1—urinary bladder cancer	5.55e-06	6.33e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—ERCC2—urinary bladder cancer	5.45e-06	6.21e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PTEN—urinary bladder cancer	5.45e-06	6.2e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—KRAS—urinary bladder cancer	5.4e-06	6.15e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—RHOA—urinary bladder cancer	5.33e-06	6.07e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.24e-06	5.97e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—EP300—urinary bladder cancer	5.19e-06	5.92e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	5.17e-06	5.88e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PPARG—urinary bladder cancer	5.14e-06	5.85e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—MTHFR—urinary bladder cancer	5.13e-06	5.84e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PTGS2—urinary bladder cancer	5.09e-06	5.8e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5e-06	5.69e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CREBBP—urinary bladder cancer	4.94e-06	5.62e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—ERBB2—urinary bladder cancer	4.94e-06	5.62e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—TYMS—urinary bladder cancer	4.8e-06	5.47e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—TP53—urinary bladder cancer	4.8e-06	5.47e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	4.75e-06	5.41e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	4.75e-06	5.41e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—HRAS—urinary bladder cancer	4.59e-06	5.23e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GPX1—urinary bladder cancer	4.55e-06	5.18e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	4.46e-06	5.08e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PTEN—urinary bladder cancer	4.44e-06	5.06e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—EP300—urinary bladder cancer	4.23e-06	4.82e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—CDKN1A—urinary bladder cancer	4.22e-06	4.8e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—PTEN—urinary bladder cancer	4.21e-06	4.79e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	4.2e-06	4.78e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PPARG—urinary bladder cancer	4.16e-06	4.73e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—EP300—urinary bladder cancer	4.01e-06	4.57e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—CREBBP—urinary bladder cancer	3.99e-06	4.55e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—SRC—urinary bladder cancer	3.9e-06	4.44e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PTEN—urinary bladder cancer	3.53e-06	4.01e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—MYC—urinary bladder cancer	3.5e-06	3.98e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—EGFR—urinary bladder cancer	3.42e-06	3.9e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PPARG—urinary bladder cancer	3.4e-06	3.87e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—EP300—urinary bladder cancer	3.36e-06	3.83e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PTGS2—urinary bladder cancer	3.27e-06	3.72e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	3.27e-06	3.72e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—KRAS—urinary bladder cancer	3.23e-06	3.68e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PTEN—urinary bladder cancer	2.85e-06	3.25e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—HRAS—urinary bladder cancer	2.75e-06	3.13e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—EP300—urinary bladder cancer	2.72e-06	3.1e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.68e-06	3.05e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.33e-06	2.66e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.23e-06	2.54e-05	CbGpPWpGaD
